Literature DB >> 1602180

Graft versus leukemia.

A Butturini1, R P Gale.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1602180     DOI： 10.1007/bf02918605

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


× No keyword cloud information.
  63 in total

1.  Indications for marrow transplantation in chronic myelogenous leukemia.

Authors:  E D Thomas; R A Clift
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

Review 2.  Biological response modifiers: the new immunotherapy.

Authors:  K A Foon
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

3.  Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes.

Authors:  Y F Shi; B M Sahai; D R Green
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

4.  Immune reactivity of leukemia patients to autologous blast cells.

Authors:  B G Leventhal; R H Halterman; E B Rosenberg; R B Herberman
Journal:  Cancer Res       Date:  1972-09       Impact factor: 12.701

5.  Syngeneic graft-versus-host disease induced by cyclosporine--a reappraisal.

Authors:  L H Chow; L Mosbach-Ozmen; B Ryffel; J F Borel
Journal:  Transplantation       Date:  1988-08       Impact factor: 4.939

6.  Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.

Authors:  D C Talbot; R L Powles; J P Sloane; J Rose; J Treleaven; H Aboud; G Helenglass; P Parikh; C Smith; M Rowley
Journal:  Bone Marrow Transplant       Date:  1990-07       Impact factor: 5.483

7.  Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

Authors:  J A Sosman; K R Oettel; S D Smith; J A Hank; P Fisch; P M Sondel
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

8.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.

Authors:  M Hauch; M V Gazzola; T Small; C Bordignon; L Barnett; I Cunningham; H Castro-Malaspinia; R J O'Reilly; C A Keever
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

9.  Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells.

Authors:  C A van Els; A Bakker; A H Zwinderman; F E Zwaan; J J van Rood; E Goulmy
Journal:  Transplantation       Date:  1990-07       Impact factor: 4.939

10.  T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.

Authors:  G Hale; S Cobbold; H Waldmann
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939
View more
  2 in total

Review 1.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

2.  Chronic GvHD decreases antiviral immune responses in allogeneic BMT.

Authors:  Mohammad S Hossain; John D Roback; Brian P Pollack; David L Jaye; Amelia Langston; Edmund K Waller
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.